Kymera Therapeutics Inc
(NAS:KYMR)
$
50.05
-1.84 (-3.55%)
Market Cap: 3.24 Bil
Enterprise Value: 2.90 Bil
PE Ratio: 0
PB Ratio: 3.63
GF Score: 47/100 Kymera Therapeutics Inc Presenting at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021 / 07:30PM GMT
Release Date Price:
$45.37
(-5.56%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Good afternoon. Welcome to the afternoon sessions of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the Senior Biopharma Analyst here. And I have Alex Hammond from my team as well with me. And we're thrilled to have Kymera Therapeutics here and speaking on behalf of Kymera is CEO, Nello Mainolfi. Nello, are you there?
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Yes, I'm here. Thanks for the invite. Great to be hear.
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Perfect. Good to see you. Yes. So before we get into some questions, do you want to kind of give us a real quick -- a real quick background and then we can get right into some of the stuff you guys have going on in the pipeline.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Excellent.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot